Open-house discount contracts for medicines with the active substance Edoxaban

Summary

Open-house discount contracts for medicines containing the active substance Edoxaban will be concluded under non-exclusive terms during 01 November 2026 to 31 October 2028, with contracts potentially concluded at any time (open-house model). In the Open House procedure, medicines are excluded according to the BfArM list under § 35 Abs. 5a SGB V (child medicines).